Reviewing CERo Therapeutics (NASDAQ:CERO) and Atyr PHARMA (NASDAQ:ATYR)

CERo Therapeutics (NASDAQ:CERO) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a summary of current ratings and price targets for CERo Therapeutics and Atyr PHARMA, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	0	0	0	0	0.00
Atyr PHARMA	0	0	5	0	3.00

Atyr PHARMA has a consensus price target of $19.25, indicating a potential upside of 456.36%. Given Atyr PHARMA’s stronger consensus rating and higher possible upside, analysts clearly believe Atyr PHARMA is more favorable than CERo Therapeutics.

Profitability

This table compares CERo Therapeutics and Atyr PHARMA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-108.43%
Atyr PHARMA	N/A	-79.44%	-59.16%

Institutional & Insider Ownership

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are held by institutional investors. 18.0% of CERo Therapeutics shares are held by company insiders. Comparatively, 3.7% of Atyr PHARMA shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares CERo Therapeutics and Atyr PHARMA”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$2.54 million	N/A	N/A
Atyr PHARMA	$350,000.00	829.81	-$50.39 million	($0.94)	-3.68

CERo Therapeutics has higher earnings, but lower revenue than Atyr PHARMA.

Volatility and Risk

CERo Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Summary

Atyr PHARMA beats CERo Therapeutics on 7 of the 10 factors compared between the two stocks.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

About Atyr PHARMA

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.